PDGFRA and gastrointestinal stromal tumor: The safety and preliminary clinical efficacy of avapritinib for PDGFRA D842V-mutant GISTs were demonstrated in the global, phase I Avapritinib in Advanced PDGFRA D842V-mutant Gastrointestinal Stromal Tumour (NAVIGATOR) study.5 An individual, open-label, phase I/II bridging study was conducted in China aiming to determine the RP2D, to evaluate the safety, and to assess the efficacy of avapritinib in Chinese patients with unresectable or metastatic GIST.